Skip to content
Peptigraph home
Shop Peptides50% off*

Mazdutide Benefits: Claims vs What Studies Show

Benefits people claim for Mazdutide, set against what published studies measured, and where no study exists.

Medical review pendingGLP-1 / glucagon dual agonistUpdated
Strongest evidence
Human RCT
Human / animal studies
8 / 0
in our evidence file (PubMed search, 2 Oct 2026)
FDA status
Not approved
Investigational in the US (approved in China)

Claimed benefits and what studies show

Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Mazdutide claimed benefits and the studies behind them
ClaimBest evidenceStudies (human / animal)What was measuredPage
Weight lossHuman RCT evidence, 4 of 48 / 0Body weight at week 60 (coprimary); Body weight at week 32 (primary); Body weight at week 24Evidence for weight loss
DiabetesHuman RCT evidence, 4 of 43 / 0HbA1c at week 24 (primary); Body weight at week 24; HbA1c vs dulaglutideEvidence for diabetes
MetabolismHuman RCT evidence, 4 of 43 / 0HbA1c at week 24 (primary); HbA1c vs dulaglutide; HbA1c at week 20 (primary)Evidence for metabolism
Heart healthReview only0 / 0Blood pressure and cholesterolEvidence for heart health

Strongest study per claim: Weight loss, JAMA 2026, PMID 42251595; Diabetes, Nature 2026, PMID 41407859; Metabolism, Nature 2026, PMID 41407859.

What the studies measured

Mazdutide outcomes in published studies
OutcomeResultStudy typeSource
Body weight at week 60 (coprimary)Body weight changed by -16.65% with mazdutide versus -1.50% with placebo at week 60.Human RCTn = 461JAMA 2026, PMID 42251595
Body weight at week 32 (primary)At 32 weeks body weight changed by -18·1% with 16 mg, -15·6% with 10 mg and -7·3% with 3-6 mg versus -0·9% with placebo.Human RCTn = 179The lancet. Diabetes & endocrinology 2026, PMID 42628555
HbA1c at week 24 (primary)HbA1c changed by -2.15% with 6 mg and -1.57% with 4 mg versus -0.14% with placebo at week 24.Human RCTn = 320Nature 2026, PMID 41407859
Body weight at week 24Body weight changed by -7.81% with 6 mg and -5.61% with 4 mg versus -1.26% with placebo.Human RCTn = 320Nature 2026, PMID 41407859
HbA1c vs dulaglutideVersus dulaglutide 1.5 mg, HbA1c differed by -0.24% (4 mg) and -0.30% (6 mg) at week 28.Human RCTn = 731Nature 2026, PMID 41407860
Body weight vs dulaglutideBody weight differed by -3.78% (4 mg) and -5.76% (6 mg) versus dulaglutide.Human RCTn = 731Nature 2026, PMID 41407860
Body weight at week 32 (primary)At week 32 body weight changed by -12.55% with 6 mg and -10.09% with 4 mg versus +0.45% with placebo.Human RCTn = 610The New England journal of medicine 2025, PMID 40421736
Body weight at week 48At week 48 body weight changed by -14.01% with 6 mg and -11.00% with 4 mg versus +0.30% with placebo.Human RCTn = 610The New England journal of medicine 2025, PMID 40421736
HbA1c at week 20 (primary)HbA1c changed by -1.41% to -1.67% with mazdutide versus -1.35% with dulaglutide and 0.03% with placebo at week 20.Human RCTDiabetes care 2024, PMID 37943529
Body weight at week 20Body weight changed by up to -7.1% with mazdutide versus -2.7% with dulaglutide and -1.4% with placebo at week 20.Human RCTDiabetes care 2024, PMID 37943529
Body weight at week 24 (primary)Body weight changed by -11.3% with 6 mg, -10.4% with 4.5 mg and -6.7% with 3 mg versus +1.0% with placebo at week 24.Human RCTn = 248Nature communications 2023, PMID 38092790
Body weight at week 12At week 12 body weight changed by -4.81% (3.0 mg), -6.40% (4.5 mg) and -6.05% (6.0 mg) versus +0.60% with placebo.Human RCTEClinicalMedicine 2021, PMID 34430840
Weight lossMazdutide reduced body weight by a mean difference of -6.22% versus placebo.Meta-analysisn = 680Frontiers in endocrinology 2024, PMID 38440786
Blood pressure and cholesterolVersus placebo, systolic BP differed by -7.57 mmHg, diastolic BP by -2.98 mmHg, total cholesterol by -16.82%, triglycerides by -43.29% and LDL by -17.07%.Meta-analysisn = 680Frontiers in endocrinology 2024, PMID 38440786
Not shown in any study we cite. Searches behind this page: PubMed search on 2 Oct 2026 for “mazdutide[tiab] OR IBI362[tiab] OR LY3305677[tiab]”: 53 results. PubMed search on 2 Oct 2026 for “(mazdutide[tiab] OR IBI362[tiab] OR LY3305677[tiab]) AND (randomized[tiab] OR trial[tiab] OR phase[tiab])”: 31 results. PubMed search on 2 Oct 2026 for “(mazdutide[tiab] OR IBI362[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab])”: 1 result.

Claimed: large weight loss

In a phase 3 trial in Chinese adults, mean body weight changed -10.09% with mazdutide at the lower dose, -12.55% at the higher dose and 0.45% with placebo at week 32.[5]

In a phase 3 trial in Chinese adults with obesity, mazdutide gave a week-60 body-weight change of -16.65% against -1.50% with placebo.[1]

In the US phase 2 trial, body weight at 32 weeks changed -18.1% with 16 mg, -15.6% with 10 mg and -7.3% with 3-6 mg, against -0.9% with placebo.[2]

Claimed: better blood sugar

In adults with type 2 diabetes, HbA1c fell 1.57% with 4 mg and 2.15% with 6 mg of mazdutide against 0.14% with placebo at week 24.[3]

Against 1.5 mg dulaglutide over 28 weeks, HbA1c differed by -0.24% with 4 mg and -0.30% with 6 mg of mazdutide.[4]

Claimed: heart and cholesterol benefits

A meta-analysis of randomized trials reported lower systolic blood pressure, diastolic pressure, total cholesterol and triglycerides with mazdutide than placebo, with heterogeneity noted for the effects.[9]

Where the evidence is thin

The meta-analysis authors concluded mazdutide appears effective for weight reduction with and without diabetes but with gastrointestinal side effects.[9]

The evidence file lists no half-life, stability study or evidence for liver health or osteoporosis for mazdutide, and the only non-Chinese weight trial is the US phase 2 study.

Calculated from evidence file web/src/data/evidence/mazdutide.json; half life found no; liver health studies 0; osteoporosis studies 0; non chinese weight trials 1. Formula: half-life values = 0; liver and bone studies = 0; non-Chinese weight trials = 1

More on Mazdutide

DosageSide effectsHow it works

Common questions

Is Mazdutide proven to work?

The strongest study we summarise for Mazdutide is human rct evidence, among 9 studies. A trial result is not an approval; see the legal status.

Does mazdutide work?

In placebo-controlled trials it produced larger weight changes than placebo; the main trials were in Chinese adults.[5]

More on Mazdutide

DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.Legal statusFDA, compounding and WADA status with dates.How to injectSites, syringe types and hygiene, step by step.For diabetesWhat research says about Mazdutide for diabetes.How it worksTarget, mechanism and how long it acts, from the label or studies.

Sources

  1. 1Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.JAMA · 2026PMID 42251595Accessed 2 Oct 2026
  2. 2Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.The lancet. Diabetes & endocrinology · 2026PMID 42628555Accessed 2 Oct 2026
  3. 3Mazdutide versus placebo in Chinese adults with type 2 diabetes.Nature · 2026PMID 41407859Accessed 2 Oct 2026
  4. 4Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.Nature · 2026PMID 41407860Accessed 2 Oct 2026
  5. 5Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.The New England journal of medicine · 2025PMID 40421736Accessed 2 Oct 2026
  6. 6Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.Diabetes care · 2024PMID 37943529Accessed 2 Oct 2026
  7. 7A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.Nature communications · 2023PMID 38092790Accessed 2 Oct 2026
  8. 8IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study.EClinicalMedicine · 2021PMID 34430840Accessed 2 Oct 2026
  9. 9Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.Frontiers in endocrinology · 2024PMID 38440786Accessed 2 Oct 2026
  10. 10PubMed search: mazdutide[tiab] OR IBI362[tiab] OR LY3305677[tiab] (53 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  11. 11PubMed search: (mazdutide[tiab] OR IBI362[tiab] OR LY3305677[tiab]) AND (randomized[tiab] OR trial[tiab] OR phase[tiab]) (31 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  12. 12PubMed search: (mazdutide[tiab] OR IBI362[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (1 result)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.